Geographical disparities in treatment and health care costs for end-of-life cancer patients in China: a retrospective study.
Cancer treatments
End-of-life (EOL)
Geographic disparities
Health care costs
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
08 Jan 2019
08 Jan 2019
Historique:
received:
28
03
2018
accepted:
20
12
2018
entrez:
10
1
2019
pubmed:
10
1
2019
medline:
16
4
2019
Statut:
epublish
Résumé
Cancer imposes substantial burdens on cancer suffers, their families and the health system, especially in the end of life (EOL) of care patients. There are few developing country studies of EOL health care costs and no specialist studies of the disparities in cancer treatment and care costs by geographical location in China. We sought to examine geographical disparities in the types of cancer treatments and care costs during the last 3 months of life for Chinese cancer patients. Using snowball sampling and face-to-face interviews, field research was conducted with a specialist questionnaire. Data were collected on 792 cancer patients who died between July 2013 and June 2016 in China. Total EOL health care costs were modeled using generalized linear models (GLMs) with log link and gamma distribution. Total health care costs were highest for urban (US$12,501) and western region (US$9808) patients and lowest for rural (US$5996) and central region (US$5814) patients. Our study revealed about 40% of the health care expenses occur in the last three months of life, and was mainly driven by hospital costs that accounted for about 70% of EOL expenditures. Patients faced out-of-pocket expenses for health care, with the ability to borrow from family and friends also impacting the type of treatment and health facility. Life-extending treatments per cancer patient was about two times that of patients receiving conservative treatments.Urban patients were more likely to receive life-extending treatments, financed by higher incomes and a greater capacity to borrow from family and friends to bridge the gap between health insurance reimbursements and out-of-pocket expenditures. Cancer patients in western region and urban area were significantly more likely to access hospice care. We found significant urban-rural and regional disparities in EOL types of cancer treatment, utilization of medical care and the health care expenditures. The EOL cancer care costs imposed heavy economic burdens in China.We recommend better clinical guidelines, improved EOL conversations and fuller information on treatment regimes among patients, family caregivers and doctors. Policies and information should pay more attention to palliative care options and the socio-cultural context of cancer care decision-making by family.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer imposes substantial burdens on cancer suffers, their families and the health system, especially in the end of life (EOL) of care patients. There are few developing country studies of EOL health care costs and no specialist studies of the disparities in cancer treatment and care costs by geographical location in China. We sought to examine geographical disparities in the types of cancer treatments and care costs during the last 3 months of life for Chinese cancer patients.
METHODS
METHODS
Using snowball sampling and face-to-face interviews, field research was conducted with a specialist questionnaire. Data were collected on 792 cancer patients who died between July 2013 and June 2016 in China. Total EOL health care costs were modeled using generalized linear models (GLMs) with log link and gamma distribution.
RESULTS
RESULTS
Total health care costs were highest for urban (US$12,501) and western region (US$9808) patients and lowest for rural (US$5996) and central region (US$5814) patients. Our study revealed about 40% of the health care expenses occur in the last three months of life, and was mainly driven by hospital costs that accounted for about 70% of EOL expenditures. Patients faced out-of-pocket expenses for health care, with the ability to borrow from family and friends also impacting the type of treatment and health facility. Life-extending treatments per cancer patient was about two times that of patients receiving conservative treatments.Urban patients were more likely to receive life-extending treatments, financed by higher incomes and a greater capacity to borrow from family and friends to bridge the gap between health insurance reimbursements and out-of-pocket expenditures. Cancer patients in western region and urban area were significantly more likely to access hospice care.
CONCLUSIONS
CONCLUSIONS
We found significant urban-rural and regional disparities in EOL types of cancer treatment, utilization of medical care and the health care expenditures. The EOL cancer care costs imposed heavy economic burdens in China.We recommend better clinical guidelines, improved EOL conversations and fuller information on treatment regimes among patients, family caregivers and doctors. Policies and information should pay more attention to palliative care options and the socio-cultural context of cancer care decision-making by family.
Identifiants
pubmed: 30621633
doi: 10.1186/s12885-018-5237-1
pii: 10.1186/s12885-018-5237-1
pmc: PMC6325809
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Subventions
Organisme : National Natural Science Foundation of China
ID : 71702131
Organisme : National Natural Science Foundation of China
ID : 71373146
Organisme : China Scholarship Council
ID : 201706220244
Références
AIDS. 2005 May;19 Suppl 2:S67-72
pubmed: 15930843
Value Health. 1999 Mar-Apr;2(2):82-7
pubmed: 16674338
J Natl Cancer Inst. 2008 May 7;100(9):630-41
pubmed: 18445825
Arch Intern Med. 2009 Mar 9;169(5):480-8
pubmed: 19273778
Soc Sci Med. 2010 Feb;70(3):392-400
pubmed: 19906477
JAMA. 2010 Mar 17;303(11):1086-7
pubmed: 20233828
BMC Cancer. 2010 Aug 02;10:400
pubmed: 20678203
Nurs Health Sci. 2010 Sep 1;12(3):369-74
pubmed: 20727089
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
Cancer. 2011 Dec 1;117(23):5383-91
pubmed: 21563177
J Natl Cancer Inst. 2011 Jun 8;103(11):853-62
pubmed: 21593012
N Engl J Med. 2011 May 26;364(21):2060-5
pubmed: 21612477
Oncology. 2011;80(1-2):118-22
pubmed: 21677456
J Palliat Care. 2011 Summer;27(2):79-88
pubmed: 21805942
NIDA Res Monogr. 1990;98:31-43
pubmed: 2234005
Health Aff (Millwood). 2012 Apr;31(4):786-96
pubmed: 22492896
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614
Drug Alcohol Depend. 2014 Feb 1;135:71-7
pubmed: 24360650
J Community Health. 2014 Oct;39(5):1012-9
pubmed: 24643730
Palliat Med. 2014 Dec;28(10):1167-96
pubmed: 24866758
PLoS Med. 2014 Sep 22;11(9):e1001694
pubmed: 25243903
Health Serv Res. 2015 Jun;50(3):690-709
pubmed: 25424134
Implement Sci. 2015 Feb 26;10:25
pubmed: 25884470
Vojnosanit Pregl. 2015 Apr;72(4):334-41
pubmed: 26040179
Palliat Med. 2015 Dec;29(10):899-907
pubmed: 26199134
Palliat Med. 2015 Dec;29(10):918-28
pubmed: 26330452
Lung Cancer. 2015 Dec;90(3):442-50
pubmed: 26439736
J Rural Health. 2016 Sep;32(4):353-362
pubmed: 26586101
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Br J Cancer. 2016 May 24;114(11):1286-92
pubmed: 27070711
BMJ Open. 2016 Apr 29;6(4):e011063
pubmed: 27130167
Medicine (Baltimore). 2016 Nov;95(44):e5216
pubmed: 27858865
BMC Palliat Care. 2017 Jun 21;17(1):1
pubmed: 28637450
Health Aff (Millwood). 2017 Jul 1;36(7):1218-1226
pubmed: 28679808
BMC Cancer. 2017 Aug 24;17(1):568
pubmed: 28836965
J Nerv Ment Dis. 1987 Sep;175(9):566-74
pubmed: 3655783